ºÝºÝߣshows by User: JonasBostrm1 / http://www.slideshare.net/images/logo.gif ºÝºÝߣshows by User: JonasBostrm1 / Fri, 09 Apr 2021 15:23:30 GMT ºÝºÝߣShare feed for ºÝºÝߣshows by User: JonasBostrm1 Where do recent small molecule clinical development candidates come from? /slideshow/where-do-recent-small-molecule-clinical-development-candidates-come-from/245983234 wheredocdscomefrompso3796939603108276020-210409152331
Presentation given at the ACS meeting in San Diego 2019. JMedChem publication available here: https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00675 ]]>
Presentation given at the ACS meeting in San Diego 2019. JMedChem publication available here: https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00675 ]]> Fri, 09 Apr 2021 15:23:30 GMT /slideshow/where-do-recent-small-molecule-clinical-development-candidates-come-from/245983234 JonasBostrm1@slideshare.net(JonasBostrm1) Where do recent small molecule clinical development candidates come from? JonasBostrm1 Presentation given at the ACS meeting in San Diego 2019. JMedChem publication available here: https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00675 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/wheredocdscomefrompso3796939603108276020-210409152331-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Presentation given at the ACS meeting in San Diego 2019. JMedChem publication available here: https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b00675
Where do recent small molecule clinical development candidates come from? from Jonas Bostræ—¦m
]]> 47 0 https://cdn.slidesharecdn.com/ss_thumbnails/wheredocdscomefrompso3796939603108276020-210409152331-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Matched-Pairs Closing the Circle /slideshow/matchedpairs-closing-the-circle/79975060 matchedpairsandringclosuresslideshare-170920112729
Talk given 2016-03 | CUP XVI | Santa Fe, NM https://www.eyesopen.com/events/2016/03/cup-16 matched-pairs and internal H-bonds]]>
Talk given 2016-03 | CUP XVI | Santa Fe, NM https://www.eyesopen.com/events/2016/03/cup-16 matched-pairs and internal H-bonds]]> Wed, 20 Sep 2017 11:27:29 GMT /slideshow/matchedpairs-closing-the-circle/79975060 JonasBostrm1@slideshare.net(JonasBostrm1) Matched-Pairs Closing the Circle JonasBostrm1 Talk given 2016-03 | CUP XVI | Santa Fe, NM https://www.eyesopen.com/events/2016/03/cup-16 matched-pairs and internal H-bonds <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/matchedpairsandringclosuresslideshare-170920112729-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Talk given 2016-03 | CUP XVI | Santa Fe, NM https://www.eyesopen.com/events/2016/03/cup-16 matched-pairs and internal H-bonds
Matched-Pairs Closing the Circle from Jonas Bostræ—¦m
]]> 247 3 https://cdn.slidesharecdn.com/ss_thumbnails/matchedpairsandringclosuresslideshare-170920112729-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 A world without (new) drugs – play it before you live it /slideshow/a-world-without-new-drugs-play-it-before-you-live-it/49380652 aworldwithoutnewdrugsplayitbeforeyouliveit-150614204920-lva1-app6891
]]>
]]> Sun, 14 Jun 2015 20:49:20 GMT /slideshow/a-world-without-new-drugs-play-it-before-you-live-it/49380652 JonasBostrm1@slideshare.net(JonasBostrm1) A world without (new) drugs – play it before you live it JonasBostrm1 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aworldwithoutnewdrugsplayitbeforeyouliveit-150614204920-lva1-app6891-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br>
A world without (new) drugs – play it before you live it from Jonas Boström
]]> 1355 4 https://cdn.slidesharecdn.com/ss_thumbnails/aworldwithoutnewdrugsplayitbeforeyouliveit-150614204920-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 The halo(gen) effect in para substituted phenyl rings - EuroCup2015 /slideshow/the-halogen-effect-in-para-substituted-phenyl-rings-euro-cup2015/48565115 thehalogeneffectinpara-substitutedphenylrings-eurocup2015-150525121424-lva1-app6891
One key to successfully progress a drug discovery project is to make first-rate decisions (hopefully) based on unambiguous data. This is not trivial since our scientific problems are often very complex and data can be fuzzy. In drug design we try to approach this uncertainty by being rational. It is however sometimes forgotten that our rational approaches may not be that rational after all – decisions may well be based on personal preferences and intuitive biases.... perhaps unconsciously made on biased data]]>
One key to successfully progress a drug discovery project is to make first-rate decisions (hopefully) based on unambiguous data. This is not trivial since our scientific problems are often very complex and data can be fuzzy. In drug design we try to approach this uncertainty by being rational. It is however sometimes forgotten that our rational approaches may not be that rational after all – decisions may well be based on personal preferences and intuitive biases.... perhaps unconsciously made on biased data]]> Mon, 25 May 2015 12:14:24 GMT /slideshow/the-halogen-effect-in-para-substituted-phenyl-rings-euro-cup2015/48565115 JonasBostrm1@slideshare.net(JonasBostrm1) The halo(gen) effect in para substituted phenyl rings - EuroCup2015 JonasBostrm1 One key to successfully progress a drug discovery project is to make first-rate decisions (hopefully) based on unambiguous data. This is not trivial since our scientific problems are often very complex and data can be fuzzy. In drug design we try to approach this uncertainty by being rational. It is however sometimes forgotten that our rational approaches may not be that rational after all – decisions may well be based on personal preferences and intuitive biases.... perhaps unconsciously made on biased data <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/thehalogeneffectinpara-substitutedphenylrings-eurocup2015-150525121424-lva1-app6891-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> One key to successfully progress a drug discovery project is to make first-rate decisions (hopefully) based on unambiguous data. This is not trivial since our scientific problems are often very complex and data can be fuzzy. In drug design we try to approach this uncertainty by being rational. It is however sometimes forgotten that our rational approaches may not be that rational after all – decisions may well be based on personal preferences and intuitive biases.... perhaps unconsciously made on biased data
The halo(gen) effect in para substituted phenyl rings - EuroCup2015 from Jonas Bostræ—¦m
]]> 669 3 https://cdn.slidesharecdn.com/ss_thumbnails/thehalogeneffectinpara-substitutedphenylrings-eurocup2015-150525121424-lva1-app6891-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Rings In (Candidate) Drugs - Case Stories /slideshow/acs-rings-incandidatedrugscasestoriesfinalbostrm/46479323 acsringsincandidatedrugscasestoriesfinalbostrm-150331014636-conversion-gate01
Selected project impacts from over a decade of using insights from computational chemistry Focus on heterocyclic rings in candidate drugs discovered at AstraZeneca/CVMD and the strategies used in their design. The case stories will include a wide variety of examples, such as (i) replacing unwanted functional groups like acids and esters with heterocyclic rings, (ii) using rings for geometrical reasons and (iii) using heterocyclic rings to fine-tune electrostatics to obtain improved properties. In most cases the key computational approach for designing candidate drugs has been the use of shape and electrostatic comparisons between molecules. The role of luck is also discussed.]]>
Selected project impacts from over a decade of using insights from computational chemistry Focus on heterocyclic rings in candidate drugs discovered at AstraZeneca/CVMD and the strategies used in their design. The case stories will include a wide variety of examples, such as (i) replacing unwanted functional groups like acids and esters with heterocyclic rings, (ii) using rings for geometrical reasons and (iii) using heterocyclic rings to fine-tune electrostatics to obtain improved properties. In most cases the key computational approach for designing candidate drugs has been the use of shape and electrostatic comparisons between molecules. The role of luck is also discussed.]]> Tue, 31 Mar 2015 01:46:36 GMT /slideshow/acs-rings-incandidatedrugscasestoriesfinalbostrm/46479323 JonasBostrm1@slideshare.net(JonasBostrm1) Rings In (Candidate) Drugs - Case Stories JonasBostrm1 Selected project impacts from over a decade of using insights from computational chemistry Focus on heterocyclic rings in candidate drugs discovered at AstraZeneca/CVMD and the strategies used in their design. The case stories will include a wide variety of examples, such as (i) replacing unwanted functional groups like acids and esters with heterocyclic rings, (ii) using rings for geometrical reasons and (iii) using heterocyclic rings to fine-tune electrostatics to obtain improved properties. In most cases the key computational approach for designing candidate drugs has been the use of shape and electrostatic comparisons between molecules. The role of luck is also discussed. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/acsringsincandidatedrugscasestoriesfinalbostrm-150331014636-conversion-gate01-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Selected project impacts from over a decade of using insights from computational chemistry Focus on heterocyclic rings in candidate drugs discovered at AstraZeneca/CVMD and the strategies used in their design. The case stories will include a wide variety of examples, such as (i) replacing unwanted functional groups like acids and esters with heterocyclic rings, (ii) using rings for geometrical reasons and (iii) using heterocyclic rings to fine-tune electrostatics to obtain improved properties. In most cases the key computational approach for designing candidate drugs has been the use of shape and electrostatic comparisons between molecules. The role of luck is also discussed.
Rings In (Candidate) Drugs - Case Stories from Jonas Bostræ—¦m
]]> 2420 15 https://cdn.slidesharecdn.com/ss_thumbnails/acsringsincandidatedrugscasestoriesfinalbostrm-150331014636-conversion-gate01-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-JonasBostrm1-48x48.jpg?cb=1617981722 http://www.pharma-iq.com/columnists/on-drug-design/ https://cdn.slidesharecdn.com/ss_thumbnails/wheredocdscomefrompso3796939603108276020-210409152331-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/where-do-recent-small-molecule-clinical-development-candidates-come-from/245983234 Where do recent small ... https://cdn.slidesharecdn.com/ss_thumbnails/matchedpairsandringclosuresslideshare-170920112729-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/matchedpairs-closing-the-circle/79975060 Matched-Pairs Closing ... https://cdn.slidesharecdn.com/ss_thumbnails/aworldwithoutnewdrugsplayitbeforeyouliveit-150614204920-lva1-app6891-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/a-world-without-new-drugs-play-it-before-you-live-it/49380652 A world without (new) ...